YSCH-01
AXP000044.1 · Oncolytic virus
- Platform
- adenovirus (Ad5, E1B-55kDa deleted; CTGVT/ZD55 design)
- Originator
- Shanghai Yuansong Biotechnology
- Sponsor
- Shanghai Yuansong Biotechnology
Names
| Name | Type | Source |
|---|---|---|
| YSCH-01 | preferred name, code | curator, ncit |
| Recombinant L-IFN adenovirus injection | synonym | ctgov |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 (ZD55/CTGVT)
- Replication
- conditionally replicating
- Modifications
- E1B-55kDa deleted
- Transgenes
- interferon (L-IFN)
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C186376
Approvals
No regulatory approval recorded.
Clinical trials (5)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07307053 | Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) | Not yet recruiting | Phase 1/2 | 2026-01-01 | 2029-01-31 | 600 | Advanced Solid Tumors; Metastatic Solid Tumors; Rare Malignant Neoplasm |
| NCT07793500 | YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC) | Recruiting | Early phase 1 | 2025-11-27 | 2026-10-09 | 36 | Advanced Solid Tumor; NSCLC |
| NCT07538128 | Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma | Recruiting | Early phase 1 | 2025-01-09 | 2026-11-27 | 10 | Recurrent Glioblastoma |
| NCT05914935 | Safety and Tolerability Study of Recombinant L-IFN Adenovirus Injection in Patients With Recurrent Glioblastoma | Unknown | Early phase 1 | 2023-06-27 | 2024-06-12 | 6 | Recurring Glioblastoma |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study | Unknown | Early phase 1 | 2021-11-30 | 2023-05-30 | 28 | Bladder Cancer; Breast Cancer; Cervical Carcinoma; Head and Neck Cancer; Lung Cancer; Melanoma; Ovarian Carcinoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38719544 | Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial. | Journal for immunotherapy of cancer | 2024 | cited by trial NCT05180851 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41339296 | Interleukin-8-induced tumor self-rampart spatially confines oncolytic virotherapy in glioblastoma. | Neuro-oncology | 2026 | name in abstract: YSCH-01 |
| PMID 40342022 | Preclinical Toxicity Study and Tissue Distribution of YSCH- 01 Injection via Intratumoral Injection, Intravenous Injection, and Intraperitoneal Injection in Syrian Hamsters. | Pharmaceutical research | 2025 | name in title: YSCH-01 |
| PMID 41372267 | Therapeutic efficacy of oncolytic adenovirus YSCH-01 in osteosarcoma evaluated in PDX and CDX mouse models. | Scientific reports | 2025 | name in title: YSCH-01 |
| PMID 37789452 | Potent antitumor efficacy of human dental pulp stem cells armed with YSCH-01 oncolytic adenovirus. | Journal of translational medicine | 2023 | name in title: YSCH-01 |
| PMID 37841695 | Double-modified oncolytic adenovirus armed with a recombinant interferon-like gene enhanced abscopal effects against malignant glioma. | Neuro-oncology advances | 2023 | name in abstract: YSCH-01 |
Notes
Recombinant oncolytic adenovirus expressing an interferon ('L-IFN'), described by its developers as cancer-targeting gene-virotherapy (CTGVT). Trials NCT05180851, NCT05914935. Originator company name taken from the product code, not from a primary source.
How to cite
YSCH-01 (AXP000044.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000044.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.